Allspring Global Investments Holdings LLC Acquires 22,170 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Allspring Global Investments Holdings LLC raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 103.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,662 shares of the company’s stock after acquiring an additional 22,170 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Hims & Hers Health were worth $389,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. FNY Investment Advisers LLC bought a new position in Hims & Hers Health in the fourth quarter valued at $48,000. Belpointe Asset Management LLC purchased a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $76,000. EMC Capital Management lifted its position in Hims & Hers Health by 80.0% in the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after buying an additional 5,332 shares during the last quarter. Corton Capital Inc. bought a new stake in Hims & Hers Health in the 3rd quarter worth approximately $122,000. Finally, QRG Capital Management Inc. purchased a new stake in Hims & Hers Health in the third quarter worth approximately $145,000. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HIMS. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 27th. Truist Financial boosted their price target on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research note on Tuesday, February 27th. SVB Leerink initiated coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 price target for the company. Imperial Capital raised Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Wednesday, February 28th. Finally, Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.85.

Hims & Hers Health Trading Up 1.9 %

Hims & Hers Health stock opened at $12.50 on Friday. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $17.16. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of -113.64 and a beta of 0.91. The business’s fifty day simple moving average is $13.75 and its two-hundred day simple moving average is $10.05.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.03. The company had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. Hims & Hers Health’s revenue for the quarter was up 47.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.05) EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.1 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Soleil Boughton sold 4,080 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the transaction, the insider now directly owns 154,345 shares in the company, valued at approximately $1,548,080.35. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $14.97, for a total value of $2,827,653.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 548,150 shares of company stock worth $7,327,717. 31.63% of the stock is owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.